SEC Form 4 · accession 0001209191-18-005293
KYNTRA BIO, INC. · KYNB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Pat Cotroneo
Officer — VP, Finance and CFO
Period of report
Jan 22, 2018
Accepted (ET)
Jan 24, 2018 · 8:37 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000921299
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 22, 2018 | M | 25,000 | $18.00 | A | 208,852 | D | |
| Common StockF1,F2 | Jan 22, 2018 | S | 11,802 | $48.28 | D | 197,050 | D | |
| Common StockF1,F3 | Jan 22, 2018 | S | 13,198 | $49.11 | D | 183,852 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $18.00 | Jan 22, 2018 | M | 25,000 | D | — | Nov 13, 2024 | Common Stock | 25,000 | 31,000 | D |
Explanation of responses
- F1Shares sold pursuant to a 10b5-1 plan.
- F2The shares were sold at prices ranging from $47.80 to $48.70. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3The shares were sold at prices ranging from $48.80 to $49.35. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in equal amounts quarterly thereafter for the following three years.